Boehringer’s Cyltezo, The Only Interchangeable Humira Biosimilar, Gets A New Form
Subcutaneous Form Has Been FDA-Approved Since 2017; Interchangeable Since 2021
Boehringer Ingelheim has welcomed a new FDA approval for its Cyltezo (adalimumab-adbm) interchangeable biosimilar, ahead of planned launch on 1 July.
You may also be interested in...
First Interchangeable Humira Biosimilar Approved In US
Boehringer Ingelheim has won a landmark first US interchangeability designation for a biosimilar to Humira, with the firm’s Cyltezo version of adalimumab representing the second ever interchangeable biosimilar approved by the FDA.
Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.